// Biotech and Pharma Therapeutics
Swiss Fire Aftermath Highlights Urgent Need For European Antimicrobial Incentives
January 28, 2026 / burn-treatment / antimicrobial-resistance / EMA-approval / sulbactam-durlobactam / EU-drug-access
A Swiss fire disaster underscores Europe’s urgent need for novel antimicrobials, as burn victims lack access to FDA-approved sulbactam-durlobactam therapy. The EMA urges faster approvals and incentives to address the antimicrobial resistance crisis.
The hidden reason cancer immunotherapy often fails
January 28, 2026 / PD-L1-vesicles / cancer-immunotherapy / UBL3-protein / statins-treatment / immune-evasion
New research shows tumors release PD-L1 via extracellular vesicles regulated by UBL3, weakening immunotherapy. Statins may block this process, offering a potential strategy to enhance cancer immunotherapy effectiveness.
Bicycle Health Appoints Rick Dean CEO to Tackle the $214B Opioid Crisis
January 27, 2026 / opioid-treatment / virtual-care / addiction-recovery / OUD-therapy / healthcare-innovation
Bicycle Health, a virtual care leader for opioid use disorder (OUD), appoints Rick Dean as CEO to expand access to evidence-based treatment amid a $214B crisis affecting 9 million Americans, aiming to scale care and improve recovery outcomes.
9 influencers shaping health information online, for better or worse
January 27, 2026 / health-influencers / medical-education / online-misinformation / public-health / digital-wellness
Online health influencers increasingly shape public health discourse, blending credible medical education with entertainment and, at times, misinformation—raising concerns about the erosion of evidence-based communication and the rise of pseudoscientific voices in digital spaces.
How Bristol Myers Squibb gave Time Back to oncologists at ASH 2025
January 23, 2026 / cancer-treatment / oncology-advancements / patient-care / time-in-medicine / Bristol-Myers-Squibb
At ASH 2025, Bristol Myers Squibb launched an oncology campaign symbolizing how innovations in cancer care give patients and providers more meaningful time, emphasizing empathy, human connection, and shared moments beyond clinical outcomes.
// 4th Industrial Revolution
Oath Surgical Launches AI-Native Surgical Centers Powered by NVIDIA
January 27, 2026 / AI-surgery / surgical-efficiency / real-time-documentation / NVIDIA-healthcare / spatial-intelligence
Oath Surgical, in partnership with NVIDIA, is launching AI-native surgical centers using real-time spatial AI to automate workflows, documentation, and data capture—aiming to improve surgical efficiency and reclaim lost clinical time.
WaPo Columnist and CMS Official Provide Dueling Narratives of ChatGPT Health
January 28, 2026 / ChatGPT-health / AI-diagnosis / digital-healthcare / cardiovascular-risk / rare-disease
Experiences with ChatGPT Health vary widely—one user received inaccurate cardiovascular assessments, while another credited it with uncovering overlooked details in a rare disease case. Experts caution against sole reliance but recognize its evolving role alongside medical providers.
Cardiac MRI breakthrough could be a game changer for assessing advanced heart failure
January 28, 2025 / cardiac-MRI / heart-failure / non-invasive-diagnosis / oxygen-saturation / catheter-alternative
Researchers developed a non-invasive method using cardiac MRI to estimate blood oxygen saturation in heart failure patients, potentially replacing risky catheterization. This breakthrough could enable safer, faster assessments, especially for frail or high-risk individuals.
Rethinking Security Among the Healthcare Workforce Crisis
January 28, 2025 / healthcare-security / workforce-crisis / AI-surveillance / cloud-access-control / hospital-safety
Amid workforce shortages and rising violence, hospitals must shift from reactive to proactive, AI-driven security models that support both staff safety and patient experience, while integrating hybrid cloud systems and data-driven insights to optimize operations.
Novel laser focal therapy device shows promising results for prostate cancer treatment
January 28, 2026 / prostate-cancer / focal-laser-therapy / minimally-invasive-oncology / prostate-ablation / clinical-trial-results
A pivotal trial of ProFocal®, a cooled laser focal therapy, showed 84% of prostate cancer patients had no clinically significant disease at 3 months, achieving effective tumor control with low incontinence and an improved safety profile versus whole-gland treatments.
// Business & Markets
Cellares raises $257 million to build ‘industrial backbone’ for cell therapy
January 28, 2026 / cell-therapy / biotech-funding / manufacturing-innovation / regenerative-medicine / Cellares-platform
Cellares raised $257 million in Series D funding to scale its integrated platform for cell therapy manufacturing, aiming to streamline and industrialize production in the growing global market for advanced cellular medicines.
Lilly allies with gene-editing firm Seamless on hearing loss
January 28, 2026 / gene-editing / hearing-loss / Eli-Lilly / Seamless-Therapeutics / recombinase-therapy
Eli Lilly partnered with Seamless Therapeutics in a $1.12B deal to develop programmable recombinase-based gene-editing therapies targeting genetic hearing loss, aiming to correct mutations with high specificity and minimal off-target effects.
BD, Waters set completion date for $17.5B biosciences and diagnostics merger
January 28, 2025 / biosciences / diagnostics / BD-Waters / healthcare-merger / lab-innovation
BD and Waters will complete their $17.5B biosciences and diagnostics merger on February 9, aiming to enhance diagnostics innovation, streamline operations, and accelerate growth through combined expertise and cost-efficiency strategies.
Teva tanks on pessimistic 2026 revenue outlook
January 28, 2026 / Teva / pharma-earnings / 2026-outlook / drugmaker-revenue / pharmaceutical-growth
Teva reported $17.3B in 2025 revenue and returned to profitability, but its stock declined due to a pessimistic 2026 outlook despite three consecutive years of growth and improved earnings.
CalciMedica stock craters as calcium channel inhibitor trial stopped over ‘safety concern’
January 28, 2026 / Auxora / kidney-injury / clinical-trial / drug-safety / biotech-setback
CalciMedica halted its phase 2 AKI trial for Auxora due to a safety concern flagged by independent review, despite no treatment-related deaths. The company plans further analysis and remains committed to developing Auxora for inflammatory diseases.
// Legal & Regulatory
FDA accepts Otsuka’s centanafadine application for ADHD treatment
January 28, 2026 / ADHD-treatment / FDA-approval / centanafadine / clinical-trials / pediatric-psychiatry
The FDA has accepted Otsuka’s NDA for centanafadine, a novel once-daily treatment for ADHD in children, adolescents, and adults, with priority review. Phase III trials showed symptom improvement and a favorable safety profile across age groups.
Gilead’s Trodelvy added to NCCN guidelines
January 28, 2026 / Trodelvy / metastatic-TNBC / NCCN-guidelines / first-line-therapy / immunotherapy
Gilead’s Trodelvy has been added to the NCCN Guidelines as a category 1 preferred first-line treatment for PD-L1-negative metastatic triple-negative breast cancer and a category 2A option with Keytruda for PD-L1-positive cases.
FDA ‘Breakthrough’ status for Biogen’s litifilimab
January 28, 2026 / litifilimab / cutaneous-lupus / breakthrough-therapy / Biogen / monoclonal-antibody
The FDA granted Breakthrough Therapy designation to Biogen’s litifilimab, a first-in-class anti-BDCA2 monoclonal antibody, for cutaneous lupus erythematosus, a chronic autoimmune skin disease currently lacking targeted treatment options.
FDA puts clinical hold on Regenxbio gene therapies weeks before approval ruling
January 28, 2025 / Regenxbio / gene-therapy / clinical-hold / RGX-111 / MPS-I
The FDA placed clinical holds on Regenxbio’s gene therapies RGX-111 and RGX-121 after detecting a CNS tumor with AAV vector integration in an RGX-111 recipient. Investigations are ongoing; RGX-121’s approval decision was expected within weeks.
Akari files new patent and advances second ADC targeting CEACAM5
January 28, 2026 / Akari / ADC-therapy / CEACAM5 / KRAS-cancer / PH1-payload
Akari Therapeutics has filed a new patent for AKTX-102, an antibody-drug conjugate targeting CEACAM5-expressing tumors. This first-in-class therapy uses Akari’s PH1 payload to deliver targeted cytotoxicity and immune activation, particularly in KRAS-mutated and hard-to-treat cancers.
// Research & Development
A triple-node heart-brain neuroimmune loop underlying myocardial infarction
January 27, 2026 / myocardial-infarction / neuroimmune-loop / vagal-neurons / IL-1β-signaling / cardiac-remodeling
Researchers identified a heart-brain neuroimmune loop involving TRPV1 vagal neurons, PVN AT1aR neurons, and SCG IL-1β signaling that drives post-MI pathology. Targeting this circuit reduces infarct size, inflammation, and cardiac dysfunction, offering novel therapeutic potential.
An uORF-encoded mobile peptide sparks systemic stomatal immunity
January 27, 2026 / USIC-peptide / systemic-immunity / stomatal-closure / plant-defense / mobile-signal
Researchers discovered that a uORF-encoded peptide, USIC, functions as a mobile signal triggering systemic stomatal immunity in plants. USIC is transported to distal leaves, activating a receptor-mediated pathway that induces stomatal closure in response to pathogen threats.
Abbott: Study shows neuromod systems greatly reduce pain-related healthcare visits
January 27, 2025 / chronic-pain / spinal-stimulation / neuromodulation-therapy / BurstDR-technology / FDA-approval
Abbott’s neuromodulation systems, including BurstDR and Proclaim DRG, reduced pain-related healthcare visits by over 70% over five years, showing sustained improvements in chronic pain management and earning FDA approval for expanded MRI compatibility.
Boehringer’s apecotrep delivers proteinuria reduction in Phase II kidney trial
January 28, 2025 / FSGS-treatment / kidney-health / proteinuria-reduction / TRPC6-inhibitor / Phase-II-trial
Boehringer Ingelheim’s apecotrep, a TRPC6 inhibitor, reduced proteinuria by 40% in a Phase II trial for focal segmental glomerulosclerosis (FSGS), showing promise as a first-in-class, non-immunosuppressive, disease-modifying kidney treatment with good tolerability.
Scientists turn tumor immune cells into cancer killers
January 28, 2025 / macrophage-reprogramming / tumor-immunotherapy / cancer-treatment / immune-cell-activation / in-situ-therapy
KAIST researchers have developed an injectable drug that reprograms tumor-associated macrophages within the tumor microenvironment, transforming them from inactive cells into active cancer killers, offering a novel in situ immunotherapy approach.
// Politics
Drugs for cancer, arthritis and HIV on Medicare’s list for 2028 price cuts
January 28, 2026 / medicare-negotiations / drug-pricing / cancer-therapies / HIV-treatment / arthritis-medicines
Medicare will negotiate 2028 price cuts on 15 high-cost drugs, including treatments for cancer, arthritis, HIV, and diabetes, under the Inflation Reduction Act—impacting $27B in spending and expanding to include some Part B physician-administered therapies.
Trump Looks To ‘Work Something Out’ After Korea Tariff Threat
January 27, 2026 / pharmaceutical-imports / korea-trade / drug-tariffs / healthcare-policy / trump-administration
Former President Trump’s threat to impose 25% tariffs on South Korean imports, including pharmaceuticals, has been softened, with a suggestion that a resolution may be negotiated to avoid impacting drug trade and bilateral healthcare collaboration.
CMS seeks ideas to shore up US supply of essential meds
January 27, 2026 / essential-medicines / supply-chain / domestic-manufacturing / cms-initiative / hospital-procurement
CMS is seeking public input to bolster U.S. production of essential medicines and PPE by incentivizing hospitals to purchase domestically made products, aiming to reduce reliance on foreign supply chains exposed during the COVID-19 pandemic.
Delhi High Court restores ban on diabetes drug combinations
January 27, 2026 / diabetes-treatment / fixed-dose-combination / india-pharma-ban / metformin-combinations / delhi-high-court
The Delhi High Court has reinstated a government ban on two fixed-dose combination drugs for type 2 diabetes, citing public health concerns. This decision impacts major Indian pharma firms and reinforces regulatory authority over drug safety.
Lisata reclaims China rights to solid tumor candidate ahead of acquisition
January 27, 2026 / certepetide / pancreatic-cancer / lisata-kuva-deal / solid-tumor-therapy / china-drug-rights
Lisata Therapeutics has regained Chinese rights to its solid tumor drug certepetide from Qilu Pharma, clearing a key milestone toward its acquisition by Kuva Labs. Certepetide is in Phase 2 trials for pancreatic ductal adenocarcinoma.